Join Global COVID-19 Vaccine Manufacturing & Supply ChainDownload Brochure
Showcase Your Solutions
Thought Leadership, Product Showcase, Lead Generation, Branding and Other Opportunities Available!Download Sponsorship Prospectus
Explore Learning & Networking Opportunities On Our Virtual Event Platform!Download Brochure
The speed with which the COVID-19 vaccine is being developed is unprecedented, and it is challenging the traditional paradigm of vaccinology science. During the COVID-19 pandemic period, scientists embarked on a race to produce safe and effective COVID-19 vaccines in record time. In less than a year, 12 vaccines have already entered clinical trials in the countries where they were approved or limited/emergency use in certain countries, 92 vaccines in clinical trials on humans, and 27 have reached the final stages of testing. At least 77 preclinical vaccines are under active investigation in animals.
Simultaneously, different stakeholders such as vaccine manufacturers and vaccine service/solution providers are working closely to ramp up COVID-19 vaccine production in order to meet the upcoming demand, with a target of up to 14 billion doses by the end of 2021. To put that figure in context, it is near twice the volume of the five billion vaccine doses of all types produced worldwide prior to the pandemic.
However, in order to vaccinate the world's population as soon as possible, additional production capacity is required. Over an 18- to 24-month period, the available global production capacity may be sufficient across all vaccine manufacturing platforms but not in a long run. In order to resolve the issue, COVID-19 vaccine manufacturers also established more than 150 partnerships with contract development and manufacturing organizations (CDMOs) to transfer technology and scale-out to increase overall production.
Also, it has become clear that many COVID-19 vaccine input supplies of raw and packaging materials, consumables, and equipment are in short supply, potentially preventing several COVID-19 vaccine manufacturers from meeting their current vaccine manufacturing commitments. For instance, the following factors have contributed to the low availability of Covid-19 vaccines in certain countries: insufficiently advanced purchasing, insufficient government investment in expanding manufacturing capacity, and insufficient coordination regarding the flow of doses from the factory to vaccination sites, information on how much is needed, and the provision of money for purchasing vaccines.
The Global COVID-19 Vaccine Manufacturing & Supply Chain 2021 conference aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration and implement additional short-term and sustainable solutions to the COVID-19 vaccine manufacturing & supply chain challenges.
- Limited data to forecast supply and manufacturing needs for COVID-19 vaccine
- Strategies to reduce the lengthy manufacturing timelines for COVID-19 vaccine
- Lack of consistency and quality control for the localized vaccine manufacturing to ensure COVID-19 vaccine's quality and safety
- Personnel and equipment that are highly specialized needed for COVID-19 vaccine manufacturing
- Lengthy production ramp-up and technology transfer timelines
- Lack of supply delivery of drug substances for COVID-19 vaccine production
- Shortfalls of global collaboration network between vaccine manufacturers and CDMOs
Zhong Kai Shi Yisheng Biopharma
Han S Kierstead AIVITA Biomedical
Raches Ella Bharat Biotech
Samir Desai Cadila Healthcare Limited (Zydus Cadila)
Mark Newman GeoVax
Randall Hyer Moderna
Joseph Payne Arcturus Therapeutics
Luis Rios-Nogales ILiAD Biotechnologies
Dr. Farshad Guirakhoo COVAXX and VAXXINITY
Kiat Ruxrungtham, MD Department of Medicine Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC)
Etleva Kadilli UNICEF
Rajinder Kumar Suri DCVMN
Ingrid Kromann CEPI
Vasan K Sambandamurthy India Alliance
Dr. Saurabh Sharma Clinton Health Access Initiative
Kevin Wang, Ph.D CC-Pharming Ltd.
Yujiao Chen Beijing CC-Pharming
Alexandre, Le Vert Osivax
Nguyen Tuyet Nga PATH
Matthew Downham CEPI
Sanjeev Kumar, Ph.D International Centre for Genetic Engineering and Biotechnology (ICGEB),
Ajoy Chakrabarti Bill & Melinda Gates Foundation
Kirill Dmitriev Russian Direct Investment Fund
Per Fischer Minervax
Ada Wong Sanofi
Dave E. Anderson VBI Vaccines
Frank Malinoski Eveliqure Biotechnologies
Daniel R. Vlock Alopexx
Dr. Gaurab Sircar Visva Bharati University, Santiniketan,
S.S Vasan CSIRO
Elena Smith Sanofi Pasteur